August 2015

Invest in health - ensuring Tomorrow, Tel Aviv Pharma-Israel (an organization of local research- and development- based pharmaceutical companies) conference held a Conference at the National Economic Conference 2015 of Kalkalist newspaper, on September 1, 2015 (Hebrew). Edith Chernovich, director-general of Pharma-Israel said, “We are at a dramatic stage in the development of original drugs". Economy Minister Arye Deri said that the country can turn into a Silicon Valley in the field of pharmaceuticals. US Ambassador Dan Shapiro reported that he has held many meetings with officials from US pharmaceutical companies that operate out of Israel. “They will continue to regard Israel as a partner and be active here,” he said. “They will continue to expand the number of their employees here. We are pleased that they are here, but there are regulatory challenges that prevent them from expanding more.”
 
The Israeli Ministry of Health will hold a workshop on regulations of clinical trials in advanced therapy. The conference is sponsored by the EU TAIEX program. The lectures will be given by guest lecturers from abroad and will discuss all aspects of the field from the perspective of European regulations. The workshop will take place on October 12-13 in Jerusalem.
 
HeartWare buys Israeli co Valtech Cardio for $800m. HeartWare International Inc. announced that it has entered into a definitive agreement to acquire Valtech Cardio Inc. in a share and milestone payments deal that could reach $857 million. Valtech is a privately held company that specializes in the development of innovative, non-invasive surgical and transcatheter valve repair and replacement devices for the treatment of the most prevalent heart valve diseases mitral valve regurgitation (MR) and tricuspid valve regurgitation (TR).
 
Teva buys 51% stake in US co Immuneering for $60m. The acquisition gives Teva exclusive rights to Immuneering’s cutting-edge analytics to advance treatments for diseases of the CNS. Immuneering Corporation is a privately-held genomic-analysis company based in Cambrige, Massachusetts. Immuneering uses advanced proprietary techniques to identify hidden signals and biological insights across an array of genetic, genomic, and proteomic data that can direct research for enhanced discovery, development and clinical success.
 
Senior executives of the pharma industry: With a small investment Israel can become a pharma nation. Senior executives of the Israeli pharma industry thinks that the priority given to generic drugs in Israel is problematic, and in order to encourage the international industry to operate in Israel, the regulation should be similar to regulation in the rest of the world. (Hebrew)
 
Israeli med tech thwarts superbugs’ takeover plans. In just a few decades, superbugs – bacteria that are resistant to antibiotics – could kill more people each year than cancer. An Israeli firm called MeMed believes it has the technology to prevent that – and last week, the European Commission gave the company three million euros to further develop its testing technology to more accurately treat patients with lower respiratory tract infections.
 
Kadimastem Proves Efficacy of Its Unique ALS Treatment in Pre-Clinical Trials. Israeli biotechnology company Kadimastem reports success in a pre-clinical trial for the treatment of ALS in another animal model. The results of the trial demonstrate the efficacy of Kadimastem’s cell-based treatment for ALS. In light of the successful conclusion of the proof of efficacy stage and the considerable advancement of the product’s development, the company intends to take another step in its process with the FDA, and file a Pre-IND in the upcoming weeks.

                       
Now live! Our new translations division of high quality certified medical and pharmaceutical translations. You are welcome to visit our new webpage: www.qt-translations.com